Plain-English translation of NCT07609914 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This study is testing , a migraine medication, to see if it's safe to take a second dose when your migraine pain doesn't fully go away about 2 hours after the first dose, or if the pain comes back later. Researchers want to make sure this approach works well and doesn't cause unwanted side effects. The study will follow participants for 24 weeks.
Some people find that their migraine pain returns even after taking their initial dose of medication. This trial wants to understand whether taking a second dose of this medication is a safe and effective option for getting relief when that happens.
You likely qualify if…
You likely don't qualify if…
You would take the medication at the start of a migraine attack. If you still have pain about 2 hours later, or if your pain returns within 24 hours, you would take a second dose. You can take a second dose up to 10 times per month. The study lasts 24 weeks, during which time you would track your migraine activity and report on how the treatment works for you and any side effects you experience.
AI-generated summary from trial data · Aug 2, 2026 · Not medical advice
United States